This invention relates to novel N-hydroxyacrylamide compounds of formula (I) and pharmaceutically acceptable salts thereof. More particularly, it relates to novel N-hydroxyacrylamide compounds and pharmaceutically acceptable salts thereof which act as a HDAC inhibitor, to a pharmaceutical composition comprising the same and to a method of using the same therapeutically in the treatment and/or prevention of HDAC-related disease. ##STR00001##

 
Web www.patentalert.com

< Apo-2 receptor polypeptides

< Lentiviral packaging constructs

> Selective inhibition of NF-.kappa.B activation by peptides designed to disrupt nemo oligomerization

> Isoxazolyl urea derivatives as kinase modulators

~ 00620